RELMADA THERAPEUTICS, INC. License and Services Revenue (Deprecated 2018-01-31)
RELMADA THERAPEUTICS, INC. (RLMD) reported License and Services Revenue (Deprecated 2018-01-31) of $7.53 thousand for the 12-month period ending 2017-06-30, per its 10-K filed 2017-09-28.
Discontinued › Income Statement › Other Income
us-gaap:LicenseAndServicesRevenue · last filed 2017-09-28
- RELMADA THERAPEUTICS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2017 was $7.53K.
| Period end | License and Services Revenue (Deprecated 2018-01-31) 12 month | License and Services Revenue (Deprecated 2018-01-31) 115 month | License and Services Revenue (Deprecated 2018-01-31) 118 month |
|---|---|---|---|
| 2017-06-30 | $7.53K 10-K · filed 2017-09-28 | ||
| 2014-03-31 | $1.50M 8-K · filed 2014-05-27 | ||
| 2013-12-31 | $1.50M 8-K · filed 2014-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |